heiBIB: Schlenk, Richard Friedrich

Schlenk, Richard Friedrich Prof. Dr. med.Universität HeidelbergHeidelberg

Publikationsliste einschränken

Publikationsjahre

Publikationstypen

Liste

Sprache

englisch (99)
deutsch (2)

Co-Autoren (Uni Heidelberg)

mehr ...

Co-Autoren (extern)

mehr ...

Publikationen in heiBIB

Bresser, Helena: Impact of TP53 mutation status in elderly AML patients when adding all-trans retinoic acid or valproic acid to decitabine / Helena Bresser, Claudia Schmoor, Olga Grishina, Dietmar Pfeifer, Johanna Thomas, Usama-Ur Rehman, Ma… , 13 October 2024. - 7 S. : Illustrationen
In: European journal of haematology, ISSN 1600-0609. 114(2025), 2 vom: Feb., Seite 231-237
DOI: 10.1111/ejh.14304
Rücker, Frank Gert: Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin / Frank G. Rücker, Lars Bullinger, Sibylle Cocciardi, Sabrina Skambraks, Tamara J. Luck, Daniela Weber… , December 10 2024. - 14 S. : Illustrationen
In: Blood advances, ISSN 2473-9537. 8(2024), 23 vom: Dez., Seite 6067-6080
DOI: 10.1182/bloodadvances.2024013758
Jaramillo Segura, Sonia: Late-onset NPM1 mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib / Sonia Jaramillo, Michael Scherer, Chelsea Szu-Tu, Sergi Beneyto-Calabuig, Carsten Müller-Tidow, Rich… , November, 2024. - 5 S. : Illustrationen
In: Haematologica, ISSN 1592-8721. 109(2024), 11 vom: Nov., Seite 3811-3815
DOI: 10.3324/haematol.2023.284922
Janssen, Maike: Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies / Maike Janssen, Albrecht Leo, Cornelia Wolf, Miriam Stenzinger, Marie Bartenschlager, Juliane Brandt,… , 9 May 2024. - 9 S.
In: International journal of cancer, ISSN 1097-0215. 155(2024), 4 vom: Aug., Seite 618-626
DOI: 10.1002/ijc.34988
Jaramillo Segura, Sonia: Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia : letters to the editor / Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Olga Eissymont,… , June, 2024. - 4 S.
In: Haematologica, ISSN 1592-8721. 109(2024), 6 vom: Juni, Seite 1973-1976
DOI: 10.3324/haematol.2023.284346
Jung, Susanne Claudia: Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3) / Susanne Jung, Richard F. Schlenk, Christopher Hackenbruch, Sandra S.L. Roldan Pinzon, Michael Bitzer… , 2024. - 11 S. : Illustrationen
In: Frontiers in oncology, ISSN 2234-943X. 14(2024), Artikel-ID 1351901, Seite 1351901-1-1351901-11
DOI: 10.3389/fonc.2024.1351901
Schlenk, Richard Friedrich: Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemia / Richard F. Schlenk, June, 2024. - 2 S.
In: Haematologica, ISSN 1592-8721. 109(2024), 6 vom: Juni, Seite 1629-1630
DOI: 10.3324/haematol.2024.285624
Kayser, Sabine: Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease / Sabine Kayser, Chiara Sartor, Fabio Giglio, Alessandro Bruno, Jonathan Webster, Patrizia Chiusolo, F… , May, 2024. - 8 S. : Illustrationen
In: Haematologica, ISSN 1592-8721. 109(2024), 5, Seite 1385-1392
DOI: 10.3324/haematol.2023.284310
Heudobler, Daniel: Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA) : results of the safety run-in phase / Daniel Heudobler, Florian Luke, Joachim Hahn, Matthias Grube, Pavla Schlosser, Stephan Kremers, Thom… , April 2024. - 5 S. : Illustrationen
In: Haematologica, ISSN 1592-8721. 109(2024), 4 vom: Apr., Seite 1274-1278
DOI: 10.3324/haematol.2023.283864
Waclawiczek, Alexander: Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to Azacitidine/Venetoclax / Alexander Waclawiczek, Aino-Maija Leppä, Simon Renders, Karolin Stumpf, Cecilia Reyneri, Barbara Bet… , June 02 2023. - 20 S. : Illustrationen
In: Cancer discovery, ISSN 2159-8290. 13(2023), 6, Seite 1408-1427
DOI: 10.1158/2159-8290.CD-22-0939
Heitmann, Jonas S.: Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease / Jonas S. Heitmann, Richard F. Schlenk, Daniela Dörfel, Sabine Kayser, Konstanze Döhner, Michael Heus… , 17 August 2023. - 9 S. : Illustrationen
In: Journal of hematology & oncology, ISSN 1756-8722. 16(2023), Artikel-ID 96, Seite 1-9
DOI: 10.1186/s13045-023-01490-w
Schmutz, Maximilian: Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen / Maximilian Schmutz, Manuela Zucknick, Richard F. Schlenk, Daniel Mertens, Axel Benner, Dieter Weiche… , 26 October 2023. - 16 S.
In: Clinical epigenetics, ISSN 1868-7083. 15(2023), Artikel-ID 171, Seite 1-16
DOI: 10.1186/s13148-023-01580-z
Röllig, Christoph: Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations : results of the SAL MIDOKIT trial : letter to the editor / Leo Ruhnke, Christoph Röllig, Sylvia Herold, Tim Sauer, Christian H. Brandts, Björn Steffen, Kerstin… , September, 2023. - 6 S. : Illustrationen
In: Haematologica, ISSN 1592-8721. 108(2023), 9 vom: Sept., Seite 2520-2525
DOI: 10.3324/haematol.2022.281636
Döhner, Hartmut: Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09) : a randomised, open-label, multicentre, phase 3 trial / Hartmut Döhner, Daniela Weber, Julia Krzykalla, Walter Fiedler, Michael W M Kühn, Thomas Schroeder, … , July 2023. - 15 S.
In: The lancet, ISSN 2352-3026. 10(2023), 7 vom: Juli, Seite e495-e509
DOI: 10.1016/S2352-3026(23)00089-3
Schlenk, Richard Friedrich: Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia / R.F. Schlenk, D. Weber, J. Krzykalla, T. Kindler, G. Wulf, B. Hertenstein, H.R. Salih, T. Südhoff, J… , 08 September 2023. - 9 S. : Illustrationen
In: Scientific reports, ISSN 2045-2322. 13(2023), Artikel-ID 14809, Seite 1-9
DOI: 10.1038/s41598-023-41964-y
Jaramillo Segura, Sonia: Q-HAM : a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD / Sonia Jaramillo, Lucian Le Cornet, Markus Kratzmann, Johannes Krisam, Martin Görner, Mathias Hänel, … , 2023. - 15 S.
In: Trials, ISSN 1468-6694. 24(2023), Artikel-ID 591, Seite 1-15
DOI: 10.1186/s13063-023-07421-x
Kayser, Sabine: Predicting successful hematopoietic stem cell collection in healthy allogeneic donors / Sabine Kayser, Richard F. Schlenk, Marcus Steiner, Harald Klüter, Patrick Wuchter, October 2023. - 7 S.
In: Transfusion medicine and hemotherapy, ISSN 1660-3818. 50(2023), 5 vom: Okt., Seite 396-402
DOI: 10.1159/000531236
Kayser, Sabine: Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia / Sabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, Mathias Hänel, Mar Tormo, Kerstin Sch… , February 23, 2023. - 8 S.
In: Haematologica, ISSN 1592-8721. 108(2023), 8 vom: Aug., Seite 2059-2066
DOI: 10.3324/haematol.2022.282127
Rummelt, Christoph: Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia : results from a randomized 2x2 phase II trial (DECIDER) / Christoph Rummelt, Olga Grishina, Claudia Schmoor, Martina Crysandt, Michael Heuser, Katharina S. Gö… , January 5, 2023. - 5 S. : Diagramme
In: Haematologica, ISSN 1592-8721. 108(2023), 8 vom: Aug., Seite 2244-2248
DOI: 10.3324/haematol.2022.282258
Kayser, Sabine: Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 / Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, Friedrich Stölzel, Cristina Gil, H. Christian R… , January, 2023. - 8 S. : Illustrationen
In: Haematologica, ISSN 1592-8721. 108(2023), 1 vom: Jan., Seite 34-41
DOI: 10.3324/haematol.2022.281137
Gaidzik, Verena Ingeborg: Palbociclib in acute Leukemias with KMT2A-rearrangement : results of AMLSG 23-14 trial / Verena I. Gaidzik, Peter Paschka, Richard F. Schlenk, Daniela Weber, Stefan Fröhling, Alwin Krämer, … , May 2023. - 4 S. : Illustrationen
In: HemaSphere, ISSN 2572-9241. 7(2023), 5 vom: Mai, Artikel-ID e877, Seite 1-4
DOI: 10.1097/HS9.0000000000000877
Erba, Harry P.: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First) : a randomised, double-blind, placebo-controlled, phase 3 trial / Harry P Erba, Pau Montesinos, Hee-Je Kim, Elżbieta Patkowska, Radovan Vrhovac, Pavel Žák, Po-Nan Wan… , 19 May 2023. - 13 S. : Illustrationen
In: The lancet, ISSN 1474-547X. 401(2023), 10388 vom: Mai, Seite 1571-1583
DOI: 10.1016/S0140-6736(23)00464-6
Othman, Jad: Overlapping features of therapy-related and de novo NPM1-mutated AML / Jad Othman, Manja Meggendorfer, Enrico Tiacci, Christian Thiede, Richard Schlenk, Richard Dillon, Se… , April 13, 2023. - 12 S.
In: Blood, ISSN 1528-0020. 141(2023), 15 vom: Apr., Seite 1846-1857
DOI: 10.1182/blood.2022018108
Schlenk, Richard Friedrich: Acute myeloid leukemia : introduction to a series highlighting progress and ongoing challenges / Richard F. Schlenk, February, 2023. - 2 S.
In: Haematologica, ISSN 1592-8721. 108(2023), 2 vom: Feb., Seite 306-307
DOI: 10.3324/haematol.2022.280803
Jaramillo Segura, Sonia: Update on current treatments for adult acute myeloid leukemia : to treat acute myeloid leukemia intensively or non-intensively? That is the question / Sonia Jaramillo and Richard F. Schlenk, February, 2023. - 11 S.
In: Haematologica, ISSN 1592-8721. 108(2023), 2 vom: Feb., Seite 342-352
DOI: 10.3324/haematol.2022.280802
Denkinger, Claudia M.: Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 : a randomized clinical trial / Claudia M. Denkinger, Maike Janssen, Ulrike Schäkel, Julia Gall, Albrecht Leo, Patrick Stelmach, Ste… , 2023. - 12 S.
In: Nature cancer, ISSN 2662-1347. 4(2023), 1, Seite 96-107
DOI: 10.1038/s43018-022-00503-w
Janssen, Maike: Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1 / Maike Janssen, Christina Schmidt, Peter-Martin Bruch, Maximilian F. Blank, Christian Rohde, Alexande… , December 15, 2022. - 17 S. : Illustrationen, Diagramme
In: Blood, ISSN 1528-0020. 140(2022), 24, Seite 2594-2610
DOI: 10.1182/blood.2021014241
Ramdohr, Florian: Atypical presentation of patients with chronic myeloid leukemia in chronic phase : case report / Florian Ramdohr, Alice Fabarius, Bettina Maier, Daniela Bretschneider, Anna Jauch, Astrid Monecke, K… , 29 August 2022. - 7 S. : Illustrationen
In: Frontiers in oncology, ISSN 2234-943X. 12(2022) vom: Aug., Artikel-ID 960914, Seite 1-7
DOI: 10.3389/fonc.2022.960914
Kubasch, Anne Sophie: Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms : results of the EUROPE trial by EMSCO : myelodysplastic neoplasms / Anne Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth, Anna Jonasova, Regina Herbst, Jose… , 07 September 2022. - 9 S.
In: Leukemia, ISSN 1476-5551. 36(2022), 10, Seite 2519-2527
DOI: 10.1038/s41375-022-01669-z
Kayser, Sabine: Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin / Sabine Kayser, Chiara Sartor, Marlise R. Luskin, Jonathan Webster, Fabio Giglio, Nydia Panitz, Andre… , September, 2022. - 8 S.
In: Haematologica, ISSN 1592-8721. 107(2022), 9, Seite 2064-2071
DOI: 10.3324/haematol.2021.280433
Döhner, Hartmut: Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications / Hartmut Döhner, Daniela Weber, Julia Krzykalla, Walter Fiedler, Gerald Wulf, Helmut Salih, Michael L… , 21 September 2022. - 11 S.
In: Blood advances, ISSN 2473-9537. 6(2022), 18 vom: Sept., Seite 5345-5355
DOI: 10.1182/bloodadvances.2022007223
Pixberg, Constantin Frederic: Cognition : a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy / C. Pixberg, M. Zapatka, M. Hlevnjak, S. Benedetto, J.P. Suppelna, J. Heil, K. Smetanay, L. Michel, C… , 21 November 2022. - 12 S.
In: ESMO open, ISSN 2059-7029. 7(2022), 6, Artikel-ID 100637, Seite 1-12
DOI: 10.1016/j.esmoop.2022.100637
Jahn, Arne: Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers / A. Jahn, A. Rump, T.J. Widmann, C. Heining, P. Horak, B. Hutter, N. Paramasivam, S. Uhrig, L. Gieldo… , 18 August 2022. - 14 S.
In: Annals of oncology, ISSN 1569-8041. 33(2022), 11, Seite 1186-1199
DOI: 10.1016/j.annonc.2022.07.008
Heilig, Christoph E.: Gene expression-based prediction of pazopanib efficacy in sarcoma / Christoph E. Heilig, Andreas Laßmann, Sadaf S. Mughal, Andreas Mock, Sebastian Pirmann, Veronica Tel… , 25 June 2022. - 12 S.
In: European journal of cancer, ISSN 1879-0852. 172(2022), Seite 107-118
DOI: 10.1016/j.ejca.2022.05.025
Kayser, Sabine: Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD : results from an international collaborative study / Sabine Kayser, Michael Kramer, David Martínez-Cuadrón, Justin Grenet, Klaus H. Metzeler, Zuzana Sust… , April 2022. - 8 S.
In: Haematologica, ISSN 1592-8721. 107(2022), 4, Seite 836-843
DOI: 10.3324/haematol.2021.278645
Tamborero, David: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology / David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Markus J… , 24 February 2022. - 11 S.
In: Nature cancer, ISSN 2662-1347. 3(2022), 2, Seite 251-261
DOI: 10.1038/s43018-022-00332-x
Heilig, Christoph E.: Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial / C.E. Heilig, P. Horak, S. Kreutzfeldt, V. Teleanu, A. Mock, M. Renner, I.A. Bhatti, B. Hutter, J. Hü… , 20 November 2021. - 5 S.
In: ESMO open, ISSN 2059-7029. 6(2021), 6, Artikel-ID 100310, Seite 1-5
DOI: 10.1016/j.esmoop.2021.100310
Kröger, Nicolaus: Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study) / Nicolaus Kröger, MD; Katja Sockel, MD; Christine Wolschke, MD; Wolfgang Bethge, MD; Richard F. Schle… , July 20, 2021. - 11 S.
In: Journal of clinical oncology, ISSN 1527-7755. 39(2021), 30, Seite 3318-3327
DOI: 10.1200/JCO.20.02724
Kayser, Sabine: Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide : an international collaborative study / Sabine Kayser, Richard F. Schlenk, Delphine Lebon, Martin Carre, Katharina S. Götze, Friedrich Stölz… , May 27, 2021. - 7 S.
In: Haematologica, ISSN 1592-8721. 106(2021), 12, Seite 3100-3106
DOI: 10.3324/haematol.2021.278722
Schmalbrock, Laura: Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin / Laura K. Schmalbrock, Anna Dolnik, Sibylle Cocciardi, Eric Sträng, Frauke Theis, Nikolaus Jahn, Ekat… , June 3, 2021. - 12 S.
In: Blood, ISSN 1528-0020. 137(2021), 22, Seite 3093-3104
DOI: 10.1182/blood.2020007626
Efficace, Fabio: Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy / Fabio Efficace, Uwe Platzbecker, Massimo Breccia, Francesco Cottone, Paola Carluccio, Prassede Salut… , 1 November 2021. - 10 S.
In: Blood advances, ISSN 2473-9537. 5(2021), 21, Seite 4370-4379
DOI: 10.1182/bloodadvances.2021004649
Teich, Katrin: Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin / Katrin Teich, Julia Krzykalla, Silke Kapp-Schwoerer, Verena I. Gaidzik, Richard F. Schlenk, Peter Pa… , May 27, 2021. - 4 S.
In: Haematologica, ISSN 1592-8721. 106(2021), 11, Seite 2986-2989
DOI: 10.3324/haematol.2021.278894
Jaramillo Segura, Sonia: Rationale and design of the 2 by 2 factorial design GnG-trial : a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML / Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Tim Sauer, Mart… , 03 November 2021. - 13 S.
In: Trials, ISSN 1468-6694. 22(2021), Artikel-ID 765, Seite 1-13
DOI: 10.1186/s13063-021-05703-w
Wass, Maxi: A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy / Maxi Wass, Stefanie Göllner, Birgit Besenbeck, Richard F. Schlenk, Petra Mundmann, Joachim R. Göther… , 2021. - 11 S. : Diagramme, Illustrationen
In: Leukemia, ISSN 1476-5551. 35(2021), 3, Seite 701-711
DOI: 10.1038/s41375-020-0892-z
Jaramillo Segura, Sonia: Post-induction treatment for acute myeloid leukemia: something change? / Sonia Jaramillo, Richard F. Schlenk, 16 July 2021. - 1-10$t10
In: Current oncology reports, ISSN 1534-6269. 23(2021), 9, Artikel-ID 109
DOI: 10.1007/s11912-021-01092-0
Jaramillo Segura, Sonia: Ruxolitinib is effective in the treatment of a patient with refractory T-ALL / Sonia Jaramillo, Hannah Hennemann, Peter Horak, Veronica Teleanu, Christoph E. Heilig, Barbara Hutte… , 2021. - 4 S.
In: eJHaem, ISSN 2688-6146. 2(2021), 1, Seite 139-142
DOI: 10.1002/jha2.143
Hecht, Anna: Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q) / Anna Hecht, Julia A. Meyer, Johann-Christoph Jann, Katja Sockel, Aristoteles Giagounidis, Katharina … , 27 April 2021. - 9 S.
In: Annals of hematology, ISSN 1432-0584. 100(2021), 6, Seite 1463-1471
DOI: 10.1007/s00277-021-04492-1
Horak, Peter: Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers / Peter Horak, Christoph Heining, Simon Kreutzfeldt, Barbara Hutter, Andreas Mock, Jennifer Hullein, M… , June 10, 2021. - 16 S.
In: Cancer discovery, ISSN 2159-8290. 11(2021), 11, Seite 2780-2795
DOI: 10.1158/2159-8290.CD-21-0126
Jahn, Nikolaus: Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication / Nikolaus Jahn, Tobias Terzer, Eric Sträng, Anna Dolnik, Sibylle Cocciardi, Ekaterina Panina, Andrea … , 21 December 2020. - 11 S.
In: Blood advances, ISSN 2473-9537. 4(2020), 24, Seite 6342-6352
DOI: 10.1182/bloodadvances.2020002673
Heitmann, Jonas S.: Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma / Jonas S. Heitmann, Juliane S. Walz, Martin Pflügler, Joseph Kauer, Richard F. Schlenk, Gundram Jung,… , October 16, 2020. - 9 S.
In: BMJ open, ISSN 2044-6055. 10(2020), 10, Artikel-ID e039639, Seite 1-9
DOI: 10.1136/bmjopen-2020-039639
Voso, Maria Teresa: Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations : a subanalysis from the RATIFY trial / Maria Teresa Voso, Richard A. Larson, Dan Jones, Guido Marcucci, Thomas Prior, Jürgen Krauter, Micha… , 13 October 2020. - 10 S.
In: Blood advances, ISSN 2473-9537. 4(2020), 19, Seite 4945-4954
DOI: 10.1182/bloodadvances.2020002904
Kapp-Schwoerer, Silke: Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML : results from the AMLSG 09-09 trial / Silke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, Verena I. Gaidzik, Peter Paschka, Jan Krönk… , August 18, 2020. - 10 S.
In: Blood, ISSN 1528-0020. 136(2020), 26, Seite 3041-3050
DOI: 10.1182/blood.2020005998
Laskin, Janessa: NRG1 fusion-driven tumors : biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents / J. Laskin, S.V. Liu, K. Tolba, C. Heining, R.F. Schlenk, P. Cheema, J. Cadranel, M.R. Jones, A. Dril… , 9 September 2020. - 11 S.
In: Annals of oncology, ISSN 1569-8041. 31(2020), 12, Seite 1693-1703
DOI: 10.1016/j.annonc.2020.08.2335
Tausch, Eugen: Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia : results from the pivotal phase III study COMPLEMENT1 / Eugen Tausch, Philipp Beck, Richard F. Schlenk, Billy J. Jebaraj, Anna Dolnik, Deyan Y. Yosifov, Pet… , January 9, 2020. - 8 S.
In: Haematologica, ISSN 1592-8721. 105(2020), 10, Seite 2440-2447
DOI: 10.3324/haematol.2019.229161
Janssen, Maike: A randomized open label phase-II clinical trial with or without infusion of plasma from subjects after convalescence of SARS-CoV-2 infection in high-risk patients with confirmed severe SARS-CoV-2 disease (RECOVER) : a structured summary of a study protocol for a randomised controlled trial / Maike Janssen, Ulrike Schäkel, Carine Djuka Fokou, Johannes Krisam, Jacek Stermann, Katharina Kriegs… , 06 October 2020. - 4 S.
In: Trials, ISSN 1468-6694. 21(2020), Artikel-ID 828, Seite 1-4
DOI: 10.1186/s13063-020-04735-y
Döhner, Konstanze: Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia / Konstanze Döhner, Christian Thiede, Nikolaus Jahn, Ekaterina Panina, Agnes Gambietz, Richard A. Lars… , 30 January 2020. - 10 S. : Diagramme
In: Blood, ISSN 1528-0020. 135(2020), 5, Seite 371-380
DOI: 10.1182/blood.2019002697
Schlenk, Richard Friedrich: Therapiestrategien bei AML / Richard Schlenk, [2020]. - 17 S.
In: Myeloische Neoplasien. (2020), Seite 150-166
Kayser, Sabine: Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study / Sabine Kayser, Robert K. Hills, Marlise R. Luskin, Andrew M. Brunner, Christine Terré, Jörg Westerma… , 2020. - 161-169$t9
In: Haematologica, ISSN 1592-8721. 105(2020), 1
DOI: 10.3324/haematol.2018.208678
Lübbert, Michael: Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia : results of a multicenter, randomized, 2 × 2, phase II trial / Michael Lübbert, MD; Olga Grishina, MD; Claudia Schmoor, PhD; Richard F. Schlenk, MD; Edgar Jost, MD… , 2019. - 14 S.
In: Journal of clinical oncology, ISSN 1527-7755. 38(2019), 3, Seite 257-270
DOI: 10.1200/JCO.19.01053
Schlenk, Richard Friedrich: Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine / R.F. Schlenk, D. Weber, W. Herr, G. Wulf, H.R. Salih, H.G. Derigs, A. Kuendgen, M. Ringhoffer, B. He… , 06 February 2019. - 11 S.
In: Leukemia, ISSN 1476-5551. 33(2019), 8, Seite 1923-1933
DOI: 10.1038/s41375-019-0395-y
Rücker, Frank Gert: Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1) : results from the AML Study Group / Frank G. Rücker, Mridul Agrawal, Andrea Corbacioglu, Daniela Weber, Silke Kapp-Schwoerer, Verena I. … , November 7, 2019. - 11 S.
In: Blood, ISSN 1528-0020. 134(2019), 19, Seite 1608-1618
DOI: 10.1182/blood.2019001425
Kubasch, Anne Sophie: Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents / Anne Sophie Kubasch, Freya Schulze, Aristoteles Giagounidis, Katharina S. Götze, Jan Krönke, Katja S… , [2020]. - 5 S. : Diagramme
In: Leukemia, ISSN 1476-5551. 34(2020), 4, Seite 1182-1186
DOI: 10.1038/s41375-019-0645-z
Weinberg, Benjamin A.: NRG1-fusion positive gastrointestinal tumours : afatinib as a novel potential treatment option / B. Weinberg, D. Renouf, H. Lim, C. Heining, R. Schlenk, M. Jones, S. Liu, A. Cseh, F. Solca, J. Lask… , 2019. - 1 S.
In: Annals of oncology, ISSN 1569-8041. 30(2019), Supplement 4, Seite iv80
DOI: 10.1093/annonc/mdz155.290
Mock, Andreas: Community-driven development of a modified progression-free survival ratio for precision oncology / Andreas Mock, Christoph E Heilig, Simon Kreutzfeldt, Daniel Huebschmann, Christoph Heining, Evelin S… , November 13, 2019. - 6 S. : Diagramme
In: ESMO open, ISSN 2059-7029. 4(2019) Artikel-Nummer e00058, 6 Seiten
DOI: 10.1136/esmoopen-2019-000583
Schlenk, Richard Friedrich: Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia : early results from the prospective randomized AMLSG 09-09 phase III study / Richard F. Schlenk, MD; Peter Paschka, MD; Julia Krzykalla, MSc; Daniela Weber, MSc; Silke Kapp-Schw… , December 18, 2019. - 10 S.
In: Journal of clinical oncology, ISSN 1527-7755. 38(2019), 6, Seite 623-632
DOI: 10.1200/JCO.19.01406
Edelmann, Dominic: Adjusting Simon's optimal two-stage design for heterogeneous populations based on stratification or using historical controls / Dominic Edelmann, Christina Habermehl, Richard F. Schlenk, Axel Benner, 2020. - 19 S.
In: Biometrical journal, ISSN 1521-4036. 62(2020), 2, Seite 311-329
DOI: 10.1002/bimj.201800390
DeAngelo, Daniel J.: Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia / Daniel J. DeAngelo, Alison R. Walker, Richard F. Schlenk, Jorge Sierra, Bruno C. Medeiros, Enrique M… , 01 August 2019. - 7 S.
In: Leukemia research, ISSN 1873-5835. 85(2019) Artikel-Nummer 106197, 7 Seiten
DOI: 10.1016/j.leukres.2019.106197
Daver, Naval: Targeting FLT3 mutations in AML : review of current knowledge and evidence / Naval Daver, Richard F. Schlenk, Nigel H. Russell, Mark J. Levis, 16 January 2019. - 14 S.
In: Leukemia, ISSN 1476-5551. 33(2019), 2, Seite 299-312
DOI: 10.1038/s41375-018-0357-9
Schlenk, Richard Friedrich: Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD / Richard F. Schlenk, Daniela Weber, Walter Fiedler, Helmut R. Salih, Gerald Wulf, Hans Salwender, Tho… , February 21, 2019. - 12 S.
In: Blood, ISSN 1528-0020. 133(2019), 8, Seite 840-851
DOI: 10.1182/blood-2018-08-869453
Döhner, Hartmut: A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia / Hartmut Döhner, Carsten Müller‐Tidow, Michael Lübbert, Walter Fiedler, Alwin Krämer, Jörg Westermann… , May 2019. - 5 S.
In: British journal of haematology, ISSN 1365-2141. 185(2019), 3, Seite 583-587
DOI: 10.1111/bjh.15563
Hütter-Krönke, Marie-Luise: Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options : results from a phase I study / Marie Luise Hütter-Krönke, Walter Fiedler, Andrea Kündgen, Jürgen Krauter, Marie von Lilienfeld-Toal… , February 2019. - 2 S.
In: Haematologica, ISSN 1592-8721. 104(2019), 2, Seite e63-e64
DOI: 10.3324/haematol.2018.199794
Schlenk, Richard Friedrich: Midostaurin : a multiple tyrosine kinases inhibitor in acute myeloid leukemia and systemic mastocytosis / Richard F. Schlenk, Sabine Kayser, 2018. - 16 S.
In: Small molecules in hematology. (2018), Seite 199-214
DOI: 10.1007/978-3-319-91439-8_10
Schlenk, Richard Friedrich: Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia : results from two clinical trials / Richard F. Schlenk, Jürgen Krauter, Emmanuel Raffoux, Karl-Anton Kreuzer, Markus Schaich, Lucien Noe… , 2018. - 4 S.
In: Haematologica, ISSN 1592-8721. 103(2018), 1, Seite e25-e28
DOI: 10.3324/haematol.2017.172411
Schlenk, Richard Friedrich: What's new in consolidation therapy in AML? / Richard F. Schlenk, Sonia Jaramillo, Carsten Müller-Tidow, 2019. - 6 S.
In: ScienceDirect. 56(2019), 2, Seite 96-101
DOI: 10.1053/j.seminhematol.2018.08.005
Kayser, Sabine: Management of patients with acute promyelocytic leukemia / Sabine Kayser, Richard F. Schlenk, Uwe Platzbecker, 24 April 2018. - 18 S.
In: Leukemia, ISSN 1476-5551. 32(2018), 6, Seite 1277-1294
DOI: 10.1038/s41375-018-0139-4
Krauter, Jürgen: Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial) / Jürgen Krauter, Walter Fiedler, Richard F. Schlenk, Peter Paschka, Felicitas Thol, Michael Lübbert, … , 30 October 2018. - 7 S.
In: British journal of haematology, ISSN 1365-2141. 183(2018), 2, Seite 235-241
DOI: 10.1111/bjh.15546
Brinker, Titus Josef: A face-aging app for smoking cessation in a waiting room setting : pilot study in an HIV outpatient clinic / Titus Josef Brinker, Christian Martin Brieske, Stefan Esser, Joachim Klode, Ute Mons, Anil Batra, To… , 15.08.18. - 12 S.
In: Journal of medical internet research, ISSN 1438-8871. 20(2018,8) Artikel-Nummer e10976, 12 Seiten
DOI: 10.2196/10976
Thol, Felicitas: Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML / Felicitas Thol, Razif Gabdoulline, Alessandro Liebich, Piroska Klement, Johannes Schiller, Christian… , September 6, 2018. - 11 S.
In: Blood, ISSN 1528-0020. 132(2018), 16, Seite 1703-1713
DOI: 10.1182/blood-2018-02-829911
Creutzig, Ursula: Acute myelogenous leukemia in adolescents and young adults / Ursula Creutzig, Matthew A. Kutny, Ronald Barr, Richard F. Schlenk, Raul C. Ribeiro, [September 2018]. - 9 S. : Diagramme
In: Pediatric blood & cancer, ISSN 1545-5017. 65 (2018,9) Artikel-Nummer 27089, Seite 1-9, 9 Seiten
DOI: 10.1002/pbc.27089
Wattad, Mohammad Amen: Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure / M. Wattad, D. Weber, K. Döhner, J. Krauter, V.I. Gaidzik, P. Paschka, M. Heuser, F. Thol, T. Kindler… , 10 February 2017. - 8 S.
In: Leukemia, ISSN 1476-5551. 31(2017), 6, Seite 1306-1313
DOI: 10.1038/leu.2017.23
Horak, Peter: Precision oncology based on omics data : the NCT Heidelberg experience / Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Se… , 09 June 2017. - 10 S.
In: International journal of cancer, ISSN 1097-0215. 141(2017), 5, Seite 877-886
DOI: 10.1002/ijc.30828
Nagel, Gabriele: Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) / Gabriele Nagel, D. Weber, E. Fromm, S. Erhardt, M. Lübbert, W. Fiedler, T. Kindler, J. Krauter, P. B… . - 11 S.
In: Annals of hematology, ISSN 1432-0584. 96(2017), 12, S. 1993-2003
DOI: 10.1007/s00277-017-3150-3
Jaramillo Segura, Sonia: Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia / S. Jaramillo, A. Benner, J. Krauter, H. Martin, T. Kindler, M. Bentz, H. R. Salih, G. Held, C.-H. Kö… , 26 May 2017. - 8 S.
In: Blood cancer journal, ISSN 2044-5385. 7(2017,5) Artikel-Nummer e564, 8 Seiten
DOI: 10.1038/bcj.2017.45
Kayser, Sabine: Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis / Sabine Kayser, Mark J. Levis, Richard F. Schlenk. - 13 S.
In: Expert review of clinical pharmacology, ISSN 1751-2441. 10(2017), 11, S. 1177-1189
DOI: 10.1080/17512433.2017.1387051
Kayser, Sabine: Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients / Sabine Kayser, Maximilian Feszler, Julia Krzykalla, Matthias Schick, Michael Kramer, Axel Benner, Fe… , 22 September 2017. - 9 S.
In: European journal of haematology, ISSN 1600-0609. 99(2017), 6, Seite 544-552
DOI: 10.1111/ejh.12972
Kayser, Sabine: Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide / S. Kayser, J. Krzykalla, M.A. Elliott, K. Norsworthy, P. Gonzales, R.K. Hills, M.R. Baer, Z. Ráčil, … , 18 April 2017. - 8 S.
In: Leukemia, ISSN 1476-5551. 31(2017), 11, Seite 2347-2354
DOI: 10.1038/leu.2017.92
Jann, Johann-Christoph: Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA / Johann-Christoph Jann, Daniel Nowak, Florian Nolte, Stephanie Fey, Verena Nowak, Julia Obländer, Jov… , 9 June 2017. - 11 S.
In: Journal of medical genetics, ISSN 1468-6244. 54(2017), 9, Seite 640-650
DOI: 10.1136/jmedgenet-2017-104528
Braulke, Friederike: Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients : results of the LE-MON-5 trial / Friederike Braulke, Xenia Schulz, Ulrich Germing, Esther Schuler, Uwe Platzbecker, Florian Nolte, Wo… , 2017. - 8 S.
In: Annals of hematology, ISSN 1432-0584. 96(2017), 6, Seite 887-894
DOI: 10.1007/s00277-017-2983-0
Schlenk, Richard Friedrich: Relapsed/refractory acute myeloid leukemia : any progress? / Richard F. Schlenk, Carsten Müller-Tidow, Axel Benner, and Meinhard Kieser, 2017. - 7 S.
In: Current opinion in oncology, ISSN 1531-703X. 29(2017), 6, Seite 467-473
DOI: 10.1097/CCO.0000000000000404
Schlenk, Richard Friedrich: Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia / RF Schlenk, P Frech, D Weber, P Brossart, H-A Horst, D Kraemer, G Held, M Ringhoffer, A Burchardt, G… . - 4 S.
In: Leukemia, ISSN 1476-5551. 31(2017), 5, S. 1217-1220
DOI: 10.1038/leu.2017.22
Schlenk, Richard Friedrich: Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis / R.F. Schlenk, F. Stegelmann, A. Reiter, E. Jost, N. Gattermann, H. Hebart, C. Waller, A. Hochhaus, U… , 2017. - 7 S.
In: Leukemia, ISSN 1476-5551. 31(2017), 4, Seite 889-895
DOI: 10.1038/leu.2016.299
Schlenk, Richard Friedrich: All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia : results of the randomized AMLSG 07-04 study / Richard F. Schlenk, Michael Lübbert, Axel Benner, Alexander Lamparter, Jürgen Krauter, Wolfgang Herr… , 3 October 2016. - 12 S.
In: Annals of hematology, ISSN 1432-0584. 95(2016), 12, Seite 1931-1942
DOI: 10.1007/s00277-016-2810-z
Schlenk, Richard Friedrich: Is there justification for 4 cycles of consolidation therapy in AML? / Richard F. Schlenk. - 4 S.
In: Best practice & research, ISSN 1532-1924. 29(2016), 4, S. 341-344
DOI: 10.1016/j.beha.2016.10.008
Schlenk, Richard Friedrich: Aktivität von Thrombozyten und deren Interaktion mit neutrophilen Granulozyten bei Patienten mit Polymyalgia rheumatica / vorgelegt von Richard Friedrich Schlenk, 2003. - 72 Bl. : graph. Darst.
Voso, Maria Teresa: Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT) / M.T. Voso, S. Martin, S. Hohaus, A. Abdallah, R.F. Schlenk, A.D. Ho and R. Haas, 26 April 2000. - 8 S. : Diagramme
In: Bone marrow transplantation, ISSN 1476-5365. 25(2000), 9, Seite 957-964
DOI: 10.1038/sj.bmt.1702336
Hohaus, Stefan: Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer / S. Hohaus, L. Funk, S. Martin, R. F. Schlenk, A. Abdallah, U. Hahn, G. Egerer, H. Goldschmidt, A. Sc… , 26 February 1999. - 8 S. : Diagramme
In: British journal of cancer, ISSN 1532-1827. 79(1999), 9, Seite 1500-1507
DOI: 10.1038/sj.bjc.6690239
Voso, Maria Teresa: Autografting with CD34+ peripheral blood stem cells : retained engraftment capability and reduced tumour cell content / Maria Teresa Voso, Stefan Hohaus, Marion Moos, Margit Pförsich, Friedrich W. Cremer, Richard F. Schl… , [1999]. - 10 S.
In: British journal of haematology, ISSN 1365-2141. 104(1999), 2, Seite 382-391
DOI: 10.1046/j.1365-2141.1999.01171.x
Schlenk, Richard Friedrich: Stratification of postremission therapy in adult myeloid leukemia according to the karyotype : preliminary results of the multicenter treatment trial AML HD93 / Richard Schlenk, Hartmut Döhner, Rainer Haas, 1998. - 10 S.
In: Experimental approaches and novel therapies. (1998), Seite 867-876
Schlenk, Richard Friedrich: Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone / R. F. Schlenk, H. Döhner, M. Pförsich, A. Benner, K. Fischer, F. Hartmann, J.Th. Fischer, W. Weber, … , November 1997. - 7 S.
In: British journal of haematology, ISSN 1365-2141. 99(1997), 2, Seite 386-393
DOI: 10.1046/j.1365-2141.1997.3933207.x
Döhner, Konstanze: Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia / Konstanze Fischer, Claudia Scholl, Jörg Sàlat, Stefan Fröhling, Richard Schlenk, Martin Bentz, Steph… , 15 November 1996. - 10 S.
In: Blood, ISSN 1528-0020. 88(1996), 10, Seite 3962-3971
DOI: 10.1182/blood.V88.10.3962.bloodjournal88103962
Döhner, Hartmut: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias / by Hartmut Döhner, Konstanze Fischer, Martin Bentz, Katrin Hansen, Axel Benner, Georges Cabot, Danie… , March 15, 1995. - 10 S.
In: Blood, ISSN 1528-0020. 85(1995), 6, Seite 1580-1589
DOI: 10.1182/blood.V85.6.1580.bloodjournal8561580

IDs

GND:

129025380

Links

Schlenk, Richard Friedrich in ...

Export Publikationsliste

heiBIB

Bei fehlerhaften oder unvollständigen Angaben wenden Sie sich bitte an biblio@ub.uni-heidelberg.de.

Informationen zu heiBIB (inkl. Einbettung der Publikationslisten in eigene WWW-Seiten).

Impressum / Datenschutz Design